With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. The post Will ...

Of all the performance suffixes you can attach to a BMW, CSL (short for Competition Sport Lightweight) may just be the one that creates the highest of expectations. Hopefully, BMW has brought its ...

When we bought the E46 M3 CSL, we said it was perfect just the way it was, but resisting modifications was never going to ...

We had reports that a beastly new CSL edition of the BMW M4 would arrive this May. It’s now May, and BMW has just unleashed a new M4 CSL, a car that — at least on paper — may lay claim to the crown as ...

CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

Steven Ewing spent his childhood reading car magazines, making his career as an automotive journalist an absolute dream job. After getting his foot in the door at Automobile while he was still a ...

CSL Behring’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. The company had been ...

In an effort to drum up hype for its newly released M4 CSL, BMW is revealing a bunch of never-before-seen CSL concepts to the public. Earlier this week it showed off a V-8-powered M3 CSL alongside the ...

“I wonder how mad they’d be if I let it out and completely ruined this Alcantara,” I thought to myself. Behind the wheel of the 2023 BMW M4 CSL, I had just done a wickedly fast run of Palm Springs’ ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...